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Abstract
Spontaneously hypertensive rat (SHR) constitutes a genetic model widely used to study the natural evolution of
hypertensive heart disease. Ca2+-handling alterations are known to occur in SHR. However, the putative modifications of
Ca2+-handling proteins during the progression to heart failure (HF) are not well established. Moreover, the role of apoptosis
in SHR is controversial. We investigated intracellular Ca2+, Ca2+-handling proteins and apoptosis in SHR vs. control Wistar
rats (W) from 3 to 15 months (mo). Changes associated with the transition to HF (i.e. lung edema and decrease in midwall
fractional shortening), occurred at 15 mo in 38% of SHR (SHRF). In SHRF, twitch and caffeine-induced Ca2+ transients,
significantly decreased relative to 6/9 mo and 15 mo without HF signs. This decrease occurred in association with a
decrease in the time constant of caffeine-Ca2+ transient decay and an increase in Na+/Ca2+ exchanger (NCX) abundance (p,
0.05) with no changes in SERCA2a expression/activity. An increased Ca2+-calmodulin-kinase II activity, associated with an
enhancement of apoptosis (TUNEL and Bax/Bcl2) was observed in SHR relative to W from 3 to 15 mo. Conclusions: 1.
Apoptosis is an early and persistent event that may contribute to hypertrophic remodeling but would not participate in the
contractile impairment of SHRF. 2. The increase in NCX expression/activity, associated with an increase in Ca2+ efflux from
the cell, constitutes a primary alteration of Ca2+-handling proteins in the evolution to HF. 3. No changes in SERCA2a
expression/activity are observed when HF signs become evident.
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Introduction
During chronic pressure overload, hypertrophy evolves to
systolic left ventricular dysfunction and heart failure (HF).
Experimental evidence suggests that a critical factor causing
cardiac decompensation after pressure overload is the failure to
preserve myocardial inotropy. Although the cause of cardiac
dysfunction in HF is multifactorial, at the myocyte level two main
mechanisms have been alleged to account for the decrease in
myocardial contractility: 1. Alterations in Ca2+-handling and 2.
Apoptosis. The first one is generally accepted as a signature feature
of experimental and human HF [1,2]. The second one is more
controversial, although several studies indicate that low levels of
chronically elevated myocyte apoptosis may play a causal role in
the process that leads to HF [3–5].
The spontaneously hypertensive rat (SHR) is a genetic
hypertension model widely used to study the natural evolution of
hypertensive heart disease similar in many aspects to human
essential hypertension. In this model, alterations in Ca2+ handling
have been described at very early stages of the disease, even before
the appearance of HF [6]. Surprisingly and in spite of the well-
recognized deregulation of Ca2+ metabolism in SHR hearts, the
mechanisms of Ca2+ handling alteration are not clear. Three main
abnormalities that may account for Ca2+ mishandling in HF have
been suggested: 1. A decrease in the expression of sarco-
endoplasmic reticulum Ca2+ ATPase (SERCA2a) relative to its
inhibitory protein phospholamban (PLN), which decreases sarco-
plasmic reticulum (SR) Ca2+ reuptake. 2. An increased expression
of Na+/Ca2+ exchanger (NCX), which enhances Ca2+ extrusion.
3. An hyperphosphorylation of the ryanodine receptor (RyR2),
which renders the channel more prone to diastolic spontaneous
Ca2+ release events (Ca2+ leak) [1,2]. All three alterations converge
to decrease the SR Ca2+ load.
Most reports studying the status of these proteins in SHR hearts
are concentrated on a single one of them and/or covered a precise
moment in the evolution of this disease. For instance, an increased
NCX activity [7,8] and either a decrease, increase or no change in
SERCA2a expression/activity was described in young SHR [9–
11]. At this stage, phosphorylation of PLN has been shown to be
increased at the Ca2+-calmodulin-dependent kinase (CaMKII) site,
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Thr17 [9,11,12]. Moreover, in old SHR failing hearts either an
increase in the abundance of NCX mRNA levels [13] or a
decrease in NCX expression, attributed to a reduction in the t-
tubular system [14], have been described. A decrease in SERCA2a
expression [14] and a PKA-dependent hyperphosphorylation of
RyR2 [15] were also observed at this later stage of the disease. In
spite of the information that they provide, these approaches
preclude a complete appraisal of the disease. This is mainly due to
the fact that a given moment in the evolution of the illness results
from a complex interplay between alterations causing cardiac
disease and remodeling, tending to restore cardiac function. One
possible strategy to gain insight into the mechanisms that lead to
HF is to follow the disease progression over long time periods.
Apoptosis has also been described either as an early phenom-
enon [12] or as a final event in SHR hearts [16,17]. However, the
cells involved (myocytes/non-myocytes), the time course and the
temporal association of the apoptotic phenomenon with the
initiation of HF, still remain unsettled.
The main goal of the present study is to provide a sequential
and mechanistic insight on the role of Ca2+-handling proteins and
their impact on Ca2+ dynamics together with the degree of
apoptosis, along the evolution to HF in SHR hearts. This strategy
may offer a more realistic interpretation of the progression of the
disease and will experimentally support new and rational
therapeutic strategies.
Materials and Methods
Ethics Statement
All procedures were performed in accordance with the Guide
for the Care and Use of Laboratory Animals [NIH Publication
No. 85–23, revised 1996] and approved by the Ethics Committee
of the Cardiovascular Research Center, National Research
Council (CCT-La Plata Consejo Nacional de Investigaciones
Cientı´ficas y Tecnolo´gicas, Argentina) (P20-2010).
Animals
Male SHR and age-matched normotensive Wistar rats (W) bred
and maintained in our animal research facility were studied at 3, 6,
9, 15 months (mo) of age. Blood pressure was monitored weekly in
non-anesthetized rats with the standard noninvasive tail cuff
method (IITC, model 29-SSP). Before the animals were sacrificed,
they were weighed and subjected to echocardiographic examina-
tion. The animals were then deeply anesthetized (35 mg/kg
sodium pentobarbital IP) and after plane three of phase III of
anesthesia was reached (verified by the loss of the corneal reflex
and appearance of slow deep diaphragmatic breathing), heart and
lungs were rapidly removed. Heart weight or lung weight-to-tibia
length ratios were calculated. Hearts were assigned for biochem-
ical studies, immunohistochemical staining (TUNEL assay),
perfusion for contractile measurements and monophasic action
potential determination or myocytes isolation for contractile and
Ca2+ measurements. At 15 mo, a number of SHR showed HF
clinical signs. The criterion to distinguish failing and non-failing
animals was the presence of at least two clinical signs (labored
breathing, tachypnea, cyanosis or diminished activity levels) and
midwall fractional shortening #24.21% and lung weight/tibial
length $7.71 mg/cm. 100, values which were two standard
deviations below or above the mean of the SHR 15 mo group,
respectively. The failing group was called SHRF and was
considered separately.
Echocardiographic Examination
Echocardiogram was performed in each rat under light
anesthesia (inhalation of isoflurane at 1.5%). Cardiac geometry
and function were evaluated by 2-dimensional M-mode echocar-
diography with a 7-MHz linear transducer (ATL G Model 11370
Ultramarc). All measurements, including left ventricular (LV) wall
thickness and diastolic dimensions, were performed according to
the American Society of Echocardiography method [18]. LV mass
was calculated as previously described [19].
Myocyte Isolation
Myocytes were isolated by enzymatic digestion [20] and kept in
a HEPES buffered solution at room temperature (20–22uC), until
used (see Methods in File S1).
Intracellular Ca2+ Dynamics
Isolated myocytes were loaded with Fura-2/AM (10 mmol/L for
15 min). Intracellular Ca2+ was measured with an epi-fluorescence
system (Ion Optix, Milton, MA). Briefly, dye-loaded cells were
placed in a chamber on the stage of an inverted microscope (Nikon
TE 2000-U) and continuously superfused with a HEPES buffered
solution at a constant flow of 1 mL/min. Experiments were
performed at room temperature (20–22uC) and myocytes were
stimulated via two-platinum electrodes on either side of the bath at
0.5 Hz. By conducting experiments under these conditions,
isolated myocytes are significantly less stressed, allowing for
prolonged stimulation protocols and extended cell viability over
time. Fura-2 fluorescence intensity was taken as an index of the
intracellular Ca2+.
SR Ca2+ content was determined by rapidly switching to a
HEPES buffered solution containing 25 mM caffeine to cause SR
Ca2+ release. The rate constant of decay of caffeine-induced Ca2+
transient (kcaff) was used to estimate the velocity of Ca2+ extrusion
by NCX (kNCX). kSERCA, was calculated by subtracting kcaff
from the rate constant of decay of systolic Ca2+ transient (kt).
These estimations assume that the decay of systolic Ca2+ transient
is due to Ca2+ removal from the cytosol by both the SR and
surface membrane mechanisms, mainly NCX, whereas the SR
does not contribute to the decay of the caffeine response [21].
SR Ca2+ leak was studied according to Shannon et al. [22]. In
short, the method consists of measuring resting Ca2+ in the
presence and absence of SR Ca2+ channel blockade by 1 mmol/L
tetracaine. After stabilization, to bring the cellular Ca2+ content to
a steady state, the stimulation was stopped and the myocytes were
exposed to 0 Na+-0 Ca2+ solution (Na+ replaced by choline
chloride) for 30 s to block the NCX, so that little or no Ca2+ can
enter or leave the resting cell. The difference in diastolic Ca2+ with
and without tetracaine was taken as an estimation of SR Ca2+ leak.
Fluorescence data were stored for an off-line analysis (ION
WIZARD fluorescence analysis software). Ca2+ transients were
analyzed as the mean value over a 10–12 records for each cell.
Heart Perfusion and Monophasic Action Potentials
Isolated hearts from SHR and W were perfused according to
the Langendorff technique at constant temperature (37uC) and
flow (14 ml) for 20 min, to evaluate contractility, relaxation and
epicardial monophasic action potentials [23] (see Methods in File
S1).
Western Blot
Heart ventricles were freeze-clamped and pulverized. Briefly,
0.1 g of tissue was homogenized in 4 volumes of lysis buffer (in
mmol/L: 30 KH2PO4, 25 NaF, 300 sucrose, 0.1 EDTA plus
Ca2+, Ca2+-Handling Proteins and Apoptosis in Hypertensive Disease
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proteases inhibitor cocktail). Protein was measured by the
Bradford method using BSA as standard. Lysates were separated
per gel line in 10% SDS polyacrilamide gel [24] or 6% SDS
polyacrilamide gel and transferred to polyvinylidene difluoride
membranes. Blots were probed overnight with the following
antibodies: Bcl-2 1:1000 (Santa Cruz biotechnology, Santa Cruz,
CA, USA), Bax 1:1000 (Santa Cruz biotechnology, Santa Cruz,
CA, USA), Sarcoplasmic Reticulum Ca2+-ATPase (SERCA2a)
1:1000 (Thermo Scientific, Rockford, IL, USA), Na+/Ca2+
exchanger (NCX) 1:1000 (Millipore, Billerica, MA, USA),
phospholamban (PLN) 1:1000 (ABR, Golden, CO, USA), Thr17
and Ser16-phosphorylated PLN 1:1000 (pThr17 and pSer16,
respectively) (1:5000 (Badrilla, Leeds, UK), Ryanodine Receptors
(RyR2) 1:1000 (ABR, Golden, CO, USA), Ser2814 and Ser2809-
phosphorylated RyR2 1:1000 (Badrilla, Leeds, UK), pCaMKII
1:1000 (Abcam, Cambridge, MA, USA). Apoptotic cell death was
determined as the ratio of the signals between the pro-apoptotic
Bax and the anti-apoptotic Bcl-2. GAPDH 1:5000 (Millipore,
Billerica, MA, USA) or calsequestrin (ABR, Golden, CO, USA)
1:2000 signals were used to normalize the signal intensity of the
different proteins. Immunoreactivity was visualized by a peroxi-
dase-based chemiluminescence detection kit (Millipore, Billerica,
MA, USA) using a Chemidoc Imaging system. The signal intensity
of the immunoblot bands was quantified using Image J software
(NIH).
TUNEL Assay
TUNEL (In Situ Cell Death Detection Kit, TMR red, Roche,
Mannheim, Germany) positive cells were imaged under a confocal
microscope (Olympus FV-1000, Japan) using a 40x NA 0.95
objective and counted in 20 random fields for each experimental
situation using the Olympus cellSens image analysis software v6.3.
Results were expressed as percentage of TUNEL positive cells
related to total number of cells. DAPI (1 ug/mL, 4, 6-Diamidino-
2-phenylindole dihydrochloride, Sigma, St Louis, MO) was used
for nuclear staining [25]. DIC (Differential Intereference Contrast)
images helped to identify cardiomyocytes and non-cardiomyocyte
cells. Cardiomyocytes were also identified following morphologic
(nuclei with elliptical shape, striated cytoplasm) and morphometric
parameters [26].
Statistics
All data are presented as mean 6 SEM. Comparisons within
groups were made by unpaired Student’s t test, as appropriate.
One-way ANOVA was used for multigroup comparisons. The
Tukey post-hoc test was used to examine statistical differences
observed with the ANOVA. A value of p,0.05 was taken to
indicate statistical significance.
Results
Progressive Development of HF in SHR
Hypertensive heart disease develops progressively in SHR from
3 to 15 mo. Systolic blood pressure and progression of hypertro-
phy (measured by left ventricular weight-to-tibial length and
echocardiography), are shown in Figure 1A–C and Table S1 in
File S1. This hypertrophic pattern has been generally considered
an adaptive mechanism to increased afterload [27]. Signs of HF,
i.e. increased lung weight-to-tibial length (LW/TL) and decreased
midwall fractional shortening (MFS), became evident at 15 mo
(Figure 1D and E) in 38% of rats (SHRF), in agreement with
previous reports, where two groups of SHR were detected, failing
and non-failing [16,28]. As shown, whereas SHR at 15 mo did not
further change LW/TL and MFS with respect to 9 mo, SHRF
showed a highly significant increase and decrease in these
Figure 1. Progression from hypertrophy to heart failure in Wistar and SHR. A) Systolic blood pressure (SBP). B) Left ventricular wall/tibial
length ratio (LVW/TL). C) Echocardiographic left ventricular mass index (LVMI). D) Lung weight-to-tibial length ratio (LW/TL). E) Left ventricle midwall
fractional shortening (MFS). All the above mentioned parameters were evaluated in normotensive (Wistar), hypertensive (SHR) and hypertensive with
significant signs of contractile failure (SHRF), at 3, 6, 9, 12 and 15 months of age. Hypertension and hypertrophy were evident from early stages in SHR
(A, B and C) while heart failure signs appeared at late stages (D and E). In 15 mo SHR, the evolution of the disease allowed to define two groups with
significantly different contractile impairment. *p,0.05 with respect to W of the same age; {p,0.05 with respect to SHR at 15 mo; n$8 animals per
point.
doi:10.1371/journal.pone.0096400.g001
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parameters, respectively, as well as changes in left ventricle
chamber dimensions at systole (Table S1 in File S1).
Intracellular Ca2+ Dynamics in Isolated Myocytes
Figure 2A and B depicts overall results of intracellular twitch
and caffeine-induced Ca2+ transient dynamics. At 6, 9 and 15 mo
there was an increase in the amplitude of Ca2+ transient and SR
Ca2+ content (caffeine-induced Ca2+ transient) in SHR vs. W
consistent with previous findings [28–31]. These two parameters
were also higher in SHR vs. 3 mo in the same strain and occur
associated with the hypertrophic phenotype of SHR (Figure 1B
and C). In contrast, in SHRF there were no significant differences
in the amplitude of twitch and caffeine Ca2+ transients with respect
to W myocytes, either relative to the same age or to SHR at 3 mo.
This different pattern was due to a significant decrease in twitch
and caffeine Ca2+ transient amplitude in SHRF myocytes with
respect to the previous stage. At 15 mo there was a significant
decrease in the time constant of caffeine-induced Ca2+ transient
decline in SHR relative to W myocytes that was even more
important in SHRF (Figure 2D and inset, left panel). The higher
velocity of caffeine-induced Ca2+ transient decay indicates an
increased NCX activity. This event may partially or totally
account for the significant decrease in caffeine and twitch Ca2+
transient amplitude in SHR and SHRF compared to 9 mo. Up-
regulation of NCX activity would be expected to promote a net
loss of Ca2+ from the cell leading to decreased diastolic Ca2+.
Indeed, diastolic Ca2+ was significantly reduced in SHRF with
respect to 15 mo W, however it was not modified in the non-
failing group (SHR) (Figure 2D inset, right panel). At 9 and 15 mo
there was an increase in SR Ca2+ leak in SHR vs. W shown in
Figure 2E. This increase could be associated with a significant
increase in SR Ca2+ content observed in SHR at these stages
(Figure 2B). The enhanced SR Ca2+ leak at 15 mo SHR could
explain the lack of change in diastolic Ca2+ observed in this group
vs. W of the same age. SR Ca2+ leak did not occur in SHRF and
therefore it cannot represent a cause of diminished contractility in
these failing rats.
Estimated activity of SERCA2a, (kSERCA2a), did not show any
difference between SHR and W myocytes all along the ages
studied (Figure 3A). However at 15 mo, SHRF show a significant
increase and decrease in the relative contribution of NCX and
SERCA2a respectively, in comparison to W and SHR (Figure 3B
and C).
Time Course of Expression and Phosphorylation of
Different Proteins Involved in Intracellular Ca2+ Handling
Figure 4 shows immunoblots (A) and overall results (B–K) of the
time course of the expression and phosphorylation of different
proteins involved in excitation-contraction coupling in cardiomy-
ocytes. The expression of NCX tended to increase at 15 mo (SHR)
and reached significant levels with respect to W, only in animals
that developed HF signs (SHRF) (Figure 4B). Our results support a
tight association between NCX overexpression (Figure 4B) and the
acceleration in the caffeine Ca2+ transient decay (Figure 2D),
which could lead, at least in part, to the decrease in the amplitude
of twitch and caffeine Ca2+ transients at the cellular level
(Figure 2A and B) and the appearance of HF signs in the intact
animal (Figure 1D and E).
Although a decrease in SERCA2a has been described as a
hallmark in cardiac failure, we could not find any difference in
either SERCA2a, PLN expression, the SERCA2a/PLN ratio
(Figure 4C, D and E) or the estimated activity of SERCA2a in
SHRF (Figure 3A) when compared to W of the same age. From
these results it is evident that a decrease in SERCA2a expression/
activity is not necessary or sufficient by itself, for the initiation of
cardiac impairment [32]. Instead, the enhancement of the ratio
NCX/SERCA2a (Figure 4F) due, in our model, to an increase in
NCX expression/activity in SHRF and the consequent Ca2+ efflux
from the cell, seems to be a requirement to decrease SR Ca2+
content with respect to previous stages and a primary event in the
impairment of heart function at this stage.
CaMKII and Thr17-PLN phosphorylations significantly in-
creased from 3 mo (Figure 4G and H). In contrast, the CaMKII
site of RyR2, Ser2814, did not change significantly (Figure 4I).
PKA-dependent Ser16 phosphorylation of PLN increased at 3 mo
and then decreased (Figure 4J) whereas Ser2808 of RyR2, a
predominant PKA site [33], did not change in the evolution from
hypertrophy to HF (Figure 4K). The dual phosphorylation of PLN
at 3 mo (Ser16 and Thr17 sites), was not associated with any
significant increase in the rate of Ca2+ transient decay (Figure 2C).
Experiments in perfused hearts from SHR and W of 3 mo also
confirmed a significant increase in PLN phosphorylation in SHR
hearts which was not associated with a relaxant effect. In these
experiments a significant prolongation of the action potential was
observed, a mechanism which could be offsetting the relaxant
effect of PLN phosphorylation (Figure S1 in File S1).
Apoptosis: An Early Event in SHR Hearts
Figure 5A and B shows western blots and overall results of the
ratio between the proapoptotic and antiapoptotic proteins, Bax
and Bcl2, respectively. From 6 mo, this ratio significantly
increased in SHR with respect to W. To further explore apoptosis,
we performed TUNEL assay at 3, and 15 mo. Of note, since we
did not detect any significant difference between values of Bax/
Bcl2 ratios in SHR and SHRF at 15 mo, both groups were
considered as a single one. This finding indicates that apoptosis
can hardly contribute to HF signs in SHR. Figure 5C and D
compares a typical example and overall results of TUNEL assay in
W and SHR. At 6 and 15 mo there was a significant increase in
total TUNEL positive nuclei relative to W. However, whereas at
6 mo this increase was due to both, myocyte and non-myocyte
cells, at 15 mo, it was mainly due to a significant increase in non-
myocyte cells (Figure 5D). Non-myocytic death was significantly
more important than myocyte death, both in SHR and W hearts
(note the different scales).
Taken together, the results indicated that apoptosis is an early
event in SHR that might influence hypertrophic remodeling in
these hearts. Apoptotic cell death persists all along the evolution
from hypertrophy to HF although the relative contribution of
myocytes and non-myocytes varied with the progression of the
disease.
Discussion
The present results depict the sequential changes of Ca2+
handling, Ca2+ handling proteins and cell death, three major
factors thought to be involved in the decreased contractility during
the progression from hypertrophy to HF in SHR. The data reveal
that the increased expression of NCX appears as a point of
inflection in the evolution to HF in this model.
The main outcomes of this study are the following: 1. An
enhancement of CaMKII activity is the first detected molecular
event associated to hypertrophy that persists to the HF stage. 2. An
early rise of myocyte apoptosis (6 and 9 mo) which, although with
a different cellular pattern, also remains until pump failure was
reached. 3. An increased expression/activity of NCX, which might
underlie, at least in part, the Ca2+ mishandling and contractile
Ca2+, Ca2+-Handling Proteins and Apoptosis in Hypertensive Disease
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deterioration of failing hearts. 4. A lack of decrease in SERCA2a
expression/activity when HF signs appeared.
The results obtained highlight the fact that there is a continuum
of different and transitory alterations in Ca2+ dynamics, Ca2+
handling proteins and cell death in the evolution from hypertro-
phy to HF. These findings may help to explain the diversity of
results obtained when these variables are studied at a given time in
the course of the disease. In addition, our results allow us to
emphasize that apoptosis and decreased SERCA2a are not
sufficient to induce heart function impairment in the SHR model.
On the other hand, the increased NCX expression/activity, and
the consequent unbalanced NCX/SERCA2a, seems to be a main
trigger event in the progression to HF.
Apoptosis and Increased CaMKII Activity: Two Early
Events in the Evolution to HF
It has been shown that very low levels of myocyte apoptosis are
observed in patients with dilated cardiomyopathy [34]. However,
other studies were unable to show apoptosis in the progression to
human HF [4]. The occurrence of apoptosis is also controversial in
SHR hearts. Whereas we recently showed apoptotic events at an
early stage [12], Zhao et al. [35] found a decrease in apoptotic
cells in hearts from SHR of a similar age. Other studies concluded
that apoptosis either increased or was not responsible for HF in
SHR [16,17]. Moreover the cell type in which apoptosis occurs
(myocytes [16] and/or non-myocytes [36]) is also under discussion.
One of the reasons of these disparate results may lie in the fact that
these previous studies assessed different single time points in the
Figure 2. Intracellular Ca2+ dynamics in isolated myocytes of Wistar and SHR. A) Twitch Ca2+ transient (CaT) amplitude. B) Caffeine (Caff)-
induced CaT amplitude. C) and D) Twitch and Caff-induced CaT decay parameters (tau). The inset in panel D) shows typical records of Caff-induced
CaT (left) and diastolic Ca2+ (right) in W and SHR at 15 mo and in SHRF. E) Ca2+ leak from the SR. CaT amplitude and SR Ca2+ content (Caff-induced
CaT) were higher in SHR at 6, 9 and 15 mo than in W of the same age. These increases were not observed in SHRF. At 15 mo there was a significant
decrease in Tau of CaT and Caff-induced CaT in SHR relative to W. Tau of Caff-induced CaT in SHRF significantly diminished with respect to 15 mo
SHR. At 9 and 15 mo there was an increase in SR Ca2+ leak in SHR vs. W, which did not occur in SHRF. *p,0.05 with respect to W of the same age;
#p,0.05 with respect to SHR at 3 mo of age; {p,0.05 with respect to SHR 15 mo; n$16 from at least 3 animals per group.
doi:10.1371/journal.pone.0096400.g002
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evolution to HF. Our results showed that apoptosis is a continuous
and significant event from 6 mo old SHR, confirming that it is an
early process in hypertensive disease. Furthermore they suggest
that apoptosis may contribute to the hypertrophic heart remod-
eling that precedes pump failure. The mixed apoptosis (myocytes
and non-myocytes) described in this work, evolved to an
exclusively non-myocyte apoptosis in the advanced stages of the
illness. The cause and consequences of this interesting finding is
out of the scope of the present study and deserves further
investigation.
In addition, our results show an increase in CaMKII activity
from 3 mo of age in SHR which persists all along the evolution
from hypertrophy to HF. This increase precedes the onset of
apoptotic cell death, reinforcing the idea of a causal relationship
between both events, as previously described [12,37,38]. More-
over, recent experiments indicated that the increased activity of
CaMKII upregulates NCX expression [39]. Thus, the increase in
CaMKII observed in the present study might be underlying the
enhancement of both, apoptosis and NCX expression.
Role of NCX in the Evolution of Hypertrophy to HF
A main finding of this study is the significant enhancement in
the estimated Ca2+ efflux through an overexpressed NCX at
15 mo in SHRF. The activity of NCX depends not only on the
kinetics properties or expression level, but also on the magnitude
and change of the driving force. The driving force is a function of
intracellular sodium ([Na+]i), [Ca
2+]i and transmembrane poten-
tial. In HF, the commonly found increased [Na+]i, prolongation of
the action potential and altered [Ca2+]i, favor the ratio reverse
mode/forward mode of NCX, decreasing Ca2+ efflux [40].
Despite this scenario, an increased Ca2+ efflux was detected in
the current experiments in SHRF which should be secondary to
the higher exchanger expression and could explain, at least in part,
the decrease in SR Ca2+ load and Ca2+ transient amplitude in the
isolated myocytes. Moreover, the finding that no significant
changes in NCX expression were observed in 15 mo SHR that did
not present HF signs, further suggests the involvement of increased
NCX expression in HF progression.
Moreover the increase in NCX expression appears as an
independent phenomenon and not as a compensatory mechanism
tending to offset the negative effects on relaxation produced by the
decrease in SERCA2a activity described in several HF models.
This conclusion is in consonance with previous results in failing
human myocardium, suggesting that regulation of the expression
of both Ca2+ transporters occurs by different independent signals
[41]. Indeed, two different phenotypes at the end stage of HF, one
with increased NCX and unchanged levels of SERCA2a and a
second one with markedly decreased SERCA2a expression and
unchanged NCX were found. Interestingly, the ratio of NCX/
SERCA2a was similar in both groups but considerably increased
compared with non-failing human heart [41]. In agreement with
this previous work, the results presented here showed that the ratio
NCX/SERCA2a was only increased at 15 mo in SHRF where
HF signs were evident.
Of note, overexpression of NCX in transgenic mice, leads to
abnormal Ca2+ handling and is responsible for a decompensatory
transition to HF under stress conditions [42], in full agreement
with the present findings.
A decreased expression of SERCA2a has been noted in some
experimental models of HF and in the failing human heart
[43,44]. Indeed, the benefits of SERCA2a adeno and adeno-
associated viral transduction in humans and in different HF
models are well documented [45,46]. However, the present results
demonstrated that the decrease in SERCA2a expression and in the
estimated SERCA2a activity, is not a necessary phenomenon for
the occurrence of cardiac dysfunction in SHR.
PLN and RyR2 Phosphorylation in the Evolution to HF
In the present experiments a sustained increase in the
phosphorylation of Thr17 site of PLN occurred from 3 mo and
persisted all along the evolution of the disease. This phosphory-
lation may have contributed to the enhancement of SR Ca2+ load
Figure 3. Activity of SERCA2a and relative contribution of NCX
and SERCA2a to the Ca2+ transient constant. A) The estimated
SERCA2a activity (kSERCA2a) did not show any difference between SHR
and W myocytes at all the time points studied. B) The relative
contribution of NCX to the Ca2+ transient decay constant was
significantly increased in SHRF. C) The relative contribution of SERCA2a
to the Ca2+ transient decay constant was significantly decreased in
SHRF. *p,0.05 with respect to W of the same age.
doi:10.1371/journal.pone.0096400.g003
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Figure 4. Time course of expression and phosphorylation of different proteins involved in intracellullar Ca2+ handling. A)
Representative immunoblots and average results of the expression and/or phosphorylation of B) NCX; C) SERCA2a; D) PLN; E) SERCA2a/PLN ratio; F)
NCX/SERCA2a ratio; G) pCaMKII; H) pThr17-PLN; I) pSer2814-RyR2; J) pSer16-PLN; K) pSer2808-RyR2. The results are expressed as percentage of values
obtained in W of the same age. Protein levels were normalized to the loading control glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Phosphorylation of PLN and RyR2 was expressed as ratio between phosphorylated and non-phosphorylated forms of the proteins. While SERCA2a
expression showed no differences at any time point studied, the expression of NCX was significantly higher only in SHRF. In this latter group, PLN
expression and SERCA2a/PLN ratio did not change with respect to W, therefore the ratio NCX/SERCA2a was significantly enhanced. CaMKII and Thr17-
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observed in isolated myocytes in SHR at 6–15 mo. However it was
not associated to any evident relaxant effect as should be expected.
A possible explanation for this finding is the prolongation of the
action potential that is known to occur in SHR [6] and that we
confirmed in the present results. This prolongation may offset the
increase in the rate of Ca2+ transient decay that should have
produced the phosphorylation of PLN. The lack of significant
increase in SR Ca2+ load and Ca2+ transient or the very modest
raise in contractility observed in 3 mo SHR myocytes and intact
hearts, is more difficult to explain, although it is not a novel
finding. Experiments by Boknik et al. [11] showed a significant
PLN phosphorylations significantly increased from 3 mo in SHR with respect to W. PKA-dependent Ser16 phosphorylation of PLN increased at 3 mo
and then decreased. Phosphorylation of Ser2808 and Ser2814 of RyR2 did not change at any age studied. *p,0.05 with respect to W of the same age;
n$4 animals per group.
doi:10.1371/journal.pone.0096400.g004
Figure 5. Apoptosis in Wistar and SHR hearts. A) Representative blots showing the expression of the proapototic (Bax) and antiapoptic (Bcl2)
proteins in Wistar (W) and SHR (S) hearts at different ages. B) Quantitative analysis of protein expression, indicate increased Bax/Bcl2 ratio in SHR
hearts at 6, 9 and 15 mo of age. (n$4 animals per group). C) Typical example of TUNEL assay of 6 mo W and SHR and D) overall results of these
experiments (n$5 animals per group). Arrows indicate myocytes and arrow heads non-myocytes. Apoptosis is an early event in SHR hearts due to
myocytes and non-myocytes death at 6 mo and to non-myocytes cells death at 15 mo. *p,0.05 with respect to W of the same age.
doi:10.1371/journal.pone.0096400.g005
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increase in PLN phosphorylation associated to a decreased
contractility in young SHR compared with normotensive animals.
The increase in Ser16 phosphorylation observed at 3 mo,
vanished at 6–15 mo consistent with an early increased sympa-
thetic tone followed by a downregulation of b-adrenergic system,
during the course of the hypertensive disease [47].
Finally we did not find any significant change in the
phosphorylation of Ser2808 and Ser2814 sites of RyR2. These
results are at odds with previous reports which described an
increase in Ser2808 and Ser2814-RyR2 phosphorylation in different
HF models [48,49]. It is possible that a slight difference in the
balance between the status of phosphatases, that are known to be
increased in HF [50,51], and the activity of kinases, may explain
the different results. In our model, RyR2 phosphorylation appears
as a mechanism not involved in the systolic dysfunction at the
failing stage and the increased SR Ca2+ leak at earlier ages can be
fully explained by the high SR Ca2+ content.
In summary, although we are aware of the fact that an increase
in NCX has been previously described in HF, these previous
studies, particularly in SHR hearts, addressed a single moment in
HF evolution and failed to show a causal relationship between the
increase in NCX and the impaired contractility. To the best of our
knowledge, this is the first study describing the sequence of the
changes of three main factors that are critical in determining the
contractile state of the heart, namely, Ca2+ handling, Ca2+
handling proteins and cell death, during the progression to HF.
These results point to the enhanced expression/activity of the
NCX and the consequent increase in the NCX/SERCA2a ratio,
as an important mechanism that may contribute to the hypocon-
tractile state typical of HF.
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Echocardiographic parameters of the different experimental
groups. Left ventricular end diastolic diameter (LVEDD); Left
ventricular end systolic diameter (LVESD); Interventricular
septum in systole (IVSs); Interventricular septum in diastole
(IVSd); Posterior wall diastolic thickness (PWdt); Posterior wall
systolic thickness (PWst). Progression of hypertrophy was observed
from 3 mo SHR in IVSs, IVSd, PWdt and PWst. Moreover,
15 mo SHRF showed a highly significant increase in LVESD and
IVSD. Values are expressed as mean6 SE. *p,0.05 vs. W. # p,
0.05 vs SHR 15 mo. Figure S1. Ex vivo experiments: perfused
hearts from Wistar and SHR at 3 mo of age. A) Representative
recordings of left ventricular developed pressure (LVDP) and
monophasic action potential (MAPs) simultaneously obtained in
Langendorff perfused hearts. B) and C) overall results of half
relaxation time (t1/2) and monophasic action potential duration at
90% repolarization (MAPD90). D) and E) typical immunoblots
and overall results of the phosphorylation of PLN at Ser16 and
Thr17 respectively. *p,0.05 with respect to Wistar hearts, n$3
animals per group.
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